Stocks To Buy

Well, well, well. Just when you thought the market was having a boring week, Thursday decided to throw us a curveball wrapped in tariffs, sprinkled with TikTok drama, and topped off with some good old-fashioned oil chaos. The Setup: When Good News Becomes Bad News So here's the thing that makes zero sense but totally makes sense if you've been watching markets long enough: The economy is actually doing great. Like, really great. The GDP got revised up to 3.8% growth (originally ...
Read More About This

Remember when buying a house felt about as realistic as buying a private jet? Well, plot twist: the housing market is stirring from its years-long hibernation, and it's got some interesting implications for your bank account. Here's the deal: mortgage rates have finally decided to chill out a bit. We're talking about a drop from the soul-crushing highs of mid-2023 to a more manageable 6.26% for a 30-year fixed mortgage. Sure, it's not the 3% fantasy land we once knew, but ...
Read More About This

Well, well, well. Looks like Amazon's "customer obsession" finally caught up with them – and by "obsession," I mean their obsession with making it impossible to cancel Prime subscriptions. The retail giant just got hit with a historic $2.5 billion fine from the FTC, and honestly? It's about time someone called them out on their subscription shenanigans. The Prime Problem Nobody Talks About Here's what went down: Amazon apparently enrolled 35 million people into Prime without their consent. You know that feeling when ...
Read More About This

So gold hit another all-time high yesterday. Shocking, right? At this point, gold setting records is about as surprising as your friend posting another gym selfie – it's happened over 30 times this year alone. But here's where it gets interesting (and slightly terrifying if you're a goldbug): history suggests this party might be winding down. The Buzzkill Data Lucas Downey, a quant wizard who actually knows what he's talking about, ran the numbers on gold's recent rampage. The SPDR Gold Trust (GLD) ...
Read More About This

So apparently Trump's on a shopping spree, and this time he's eyeing Lithium Americas (LAC) like it's the last slice of pizza at a tech conference. Word on the street is that Uncle Sam wants to grab up to a 10% stake in the company while renegotiating a $2.26 billion Energy Department loan. And boy, did the market notice—LAC shares absolutely rocketed 80% in after-hours trading yesterday. Here's the deal: America currently produces about as much lithium as a small mining ...
Read More About This

So here's the thing about September – it's supposed to be the market's villain origin story. Historically, it's been the worst month for stocks, with the S&P 500 managing to stay positive only 44.9% of the time since 1928. September is basically the market equivalent of that friend who always cancels plans last minute. Except this year, September decided to be the overachiever nobody saw coming. Through the first three weeks, the S&P 500 jumped 3.2%, the Dow climbed 1.7%, and the ...
Read More About This

So here's a head-scratcher for you: What do you call a company that absolutely crushes earnings expectations, beats revenue forecasts, and has analysts falling over themselves to raise price targets... but still sees its stock price drop? If you guessed "Micron Technology," congratulations – you've just witnessed one of the market's most confusing magic tricks. The Numbers Don't Lie (But Apparently They Don't Matter Either) Let's talk about what Micron (NASDAQ: MU) just pulled off in their Q4 earnings. This memory chip ...
Read More About This

So here's a wild Tuesday for you: UniQure (QURE) decided to casually drop some news that sent their stock absolutely parabolic – we're talking a 250% surge that had it flirting with $50. Why? They might have just cracked the code on Huntington's disease. Let me break this down without the medical jargon that usually makes your eyes glaze over. UniQure released Phase 1/2 data for something called AMT-130, which is basically their experimental gene therapy for Huntington's disease. The results? ...
Read More About This